🚀 VC round data is live in beta, check it out!
Integra Lifesciences Valuation Multiples
Discover revenue and EBITDA valuation multiples for Integra Lifesciences and similar public comparables like QuidelOrtho, PHC Holdings, MedCap, InMode and more.
Integra Lifesciences Overview
About Integra Lifesciences
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales.
Founded
1969
HQ
Employees
4.4K
Website
Financials (LTM)
EV
$3B
Integra Lifesciences Financials
Integra Lifesciences reported last 12-month revenue of $2B and EBITDA of $320M.
In the same LTM period, Integra Lifesciences generated $1B in gross profit, $320M in EBITDA, and $174M in net income.
Revenue (LTM)
Integra Lifesciences P&L
In the most recent fiscal year, Integra Lifesciences reported revenue of $2B and EBITDA of $316M.
Integra Lifesciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $2B | XXX | $2B | XXX | XXX | XXX |
| Gross Profit | $1B | XXX | $832M | XXX | XXX | XXX |
| Gross Margin | 62% | XXX | 51% | XXX | XXX | XXX |
| EBITDA | $320M | XXX | $316M | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | 19% | XXX | XXX | XXX |
| EBIT Margin | 17% | XXX | 17% | XXX | XXX | XXX |
| Net Profit | $174M | XXX | $171M | XXX | XXX | XXX |
| Net Margin | 11% | XXX | 10% | XXX | XXX | XXX |
| Net Debt | — | — | $2B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Integra Lifesciences Stock Performance
Integra Lifesciences has current market cap of $869M, and enterprise value of $3B.
Market Cap Evolution
Integra Lifesciences' stock price is $11.15.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3B | $869M | 0.0% | XXX | XXX | XXX | $2.20 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialIntegra Lifesciences Valuation Multiples
Integra Lifesciences trades at 1.6x EV/Revenue multiple, and 8.3x EV/EBITDA.
EV / Revenue (LTM)
Integra Lifesciences Financial Valuation Multiples
As of April 19, 2026, Integra Lifesciences has market cap of $869M and EV of $3B.
Equity research analysts estimate Integra Lifesciences' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Integra Lifesciences has a P/E ratio of 5.0x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $869M | XXX | $869M | XXX | XXX | XXX |
| EV (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV/Revenue | 1.6x | XXX | 1.6x | XXX | XXX | XXX |
| EV/EBITDA | 8.3x | XXX | 8.3x | XXX | XXX | XXX |
| EV/EBIT | 9.6x | XXX | 9.7x | XXX | XXX | XXX |
| EV/Gross Profit | 2.6x | XXX | 3.2x | XXX | XXX | XXX |
| P/E | 5.0x | XXX | 5.1x | XXX | XXX | XXX |
| EV/FCF | 128.6x | XXX | (85.0x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Integra Lifesciences Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Integra Lifesciences Margins & Growth Rates
Integra Lifesciences' revenue in the last 12 month grew by 3%.
Integra Lifesciences' revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.2M for the same period.
Integra Lifesciences' rule of 40 is 22% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Integra Lifesciences' rule of X is 26% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Integra Lifesciences Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 3% | XXX | 2% | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | 19% | XXX | XXX | XXX |
| EBITDA Growth | 5% | XXX | 4% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 22% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 26% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| R&D Expenses to Revenue | 5% | XXX | 6% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 50% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Integra Lifesciences Public Comps
See public comps and valuation multiples for other Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Integra Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| QuidelOrtho | XXX | XXX | XXX | XXX | XXX | XXX |
| PHC Holdings | XXX | XXX | XXX | XXX | XXX | XXX |
| MedCap | XXX | XXX | XXX | XXX | XXX | XXX |
| InMode | XXX | XXX | XXX | XXX | XXX | XXX |
| Barco | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Integra Lifesciences M&A Activity
Integra Lifesciences acquired XXX companies to date.
Last acquisition by Integra Lifesciences was on XXXXXXXX, XXXXX. Integra Lifesciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Integra Lifesciences
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialIntegra Lifesciences Investment Activity
Integra Lifesciences invested in XXX companies to date.
Integra Lifesciences made its latest investment on XXXXXXXX, XXXXX. Integra Lifesciences invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Integra Lifesciences
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Integra Lifesciences
| When was Integra Lifesciences founded? | Integra Lifesciences was founded in 1969. |
| Where is Integra Lifesciences headquartered? | Integra Lifesciences is headquartered in United States. |
| How many employees does Integra Lifesciences have? | As of today, Integra Lifesciences has over 4K employees. |
| Who is the CEO of Integra Lifesciences? | Integra Lifesciences' CEO is Mojdeh Poul. |
| Is Integra Lifesciences publicly listed? | Yes, Integra Lifesciences is a public company listed on Nasdaq. |
| What is the stock symbol of Integra Lifesciences? | Integra Lifesciences trades under IART ticker. |
| When did Integra Lifesciences go public? | Integra Lifesciences went public in 1995. |
| Who are competitors of Integra Lifesciences? | Integra Lifesciences main competitors are QuidelOrtho, PHC Holdings, MedCap, InMode. |
| What is the current market cap of Integra Lifesciences? | Integra Lifesciences' current market cap is $869M. |
| What is the current revenue of Integra Lifesciences? | Integra Lifesciences' last 12 months revenue is $2B. |
| What is the current revenue growth of Integra Lifesciences? | Integra Lifesciences revenue growth (NTM/LTM) is 3%. |
| What is the current EV/Revenue multiple of Integra Lifesciences? | Current revenue multiple of Integra Lifesciences is 1.6x. |
| Is Integra Lifesciences profitable? | Yes, Integra Lifesciences is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Integra Lifesciences? | Integra Lifesciences' last 12 months EBITDA is $320M. |
| What is Integra Lifesciences' EBITDA margin? | Integra Lifesciences' last 12 months EBITDA margin is 19%. |
| What is the current EV/EBITDA multiple of Integra Lifesciences? | Current EBITDA multiple of Integra Lifesciences is 8.3x. |
| What is the current FCF of Integra Lifesciences? | Integra Lifesciences' last 12 months FCF is $21M. |
| What is Integra Lifesciences' FCF margin? | Integra Lifesciences' last 12 months FCF margin is 1%. |
| What is the current EV/FCF multiple of Integra Lifesciences? | Current FCF multiple of Integra Lifesciences is 128.6x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.